Entera Bio (ENTX) Short-term Investments (2017 - 2025)

Entera Bio (ENTX) recorded quarterly Short-term Investments of $7.8 million in Q4 2025, up 3434.09% on a QoQ basis from $220000.0 in Q4 2018.

Entera Bio (ENTX) Short-term Investments (2017 - 2025) Analysis & Trends

Entera Bio has disclosed Short-term Investments across 3 years of filings, most recently posting $7.8 million for Q4 2025.

Quarterly Short-term Investments changed N/A year-over-year to $7.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.8 million (changed N/A YoY) and the FY2025 annual result came in at $7.8 million, changed N/A from the prior year.
Short-term Investments rose to $7.8 million in Q4 2025, from $220000.0 in the prior quarter.
Over five years, Short-term Investments peaked at $7.8 million in Q4 2025 and troughed at $7.8 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn
9	Abivax	94.37 Bn	94.37 Bn	-
10	Entera Bio	56.59 Mn	52.45 Mn	-

Download Data